Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health logo
$12.67 -0.08 (-0.63%)
(As of 11/14/2024 ET)

Evolent Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
11

Based on 12 Wall Street analysts who have issued ratings for Evolent Health in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 1 has given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for EVH.

Consensus Price Target

$29.50
132.83% Upside
According to the 12 analysts' twelve-month price targets for Evolent Health, the average price target is $29.50. The highest price target for EVH is $45.00, while the lowest price target for EVH is $16.00. The average price target represents a forecasted upside of 132.83% from the current price of $12.67.

EVH Analyst Ratings Over Time

TypeCurrent Forecast
11/16/23 to 11/15/24
1 Month Ago
10/17/23 to 10/16/24
3 Months Ago
8/18/23 to 8/17/24
1 Year Ago
11/16/22 to 11/16/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$29.50$39.91$41.10$47.00
Forecasted Upside132.83% Upside50.49% Upside50.11% Upside59.54% Upside
Consensus Rating
Buy
Buy
Buy
Moderate Buy

EVH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EVH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Evolent Health Stock vs. The Competition

TypeEvolent HealthComputer and Technology CompaniesS&P 500
Consensus Rating Score
3.00
2.67
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside132.83% Upside564.68% Upside8.87% Upside
News Sentiment Rating
Neutral News

See Recent EVH News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/13/2024Citigroup
3 of 5 stars
 Lower TargetBuy ➝ Buy$33.00 ➝ $21.00+64.06%
11/12/2024Royal Bank of Canada
4 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$20.00 ➝ $20.00+35.04%
11/11/2024Barclays
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$39.00 ➝ $19.00+37.68%
11/8/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$45.00 ➝ $34.00+129.57%
11/8/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Garro
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$38.00 ➝ $16.00-34.93%
10/11/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$35.00+30.60%
Urgent: This election is rigged (Ad)

If you missed it, my emergency election broadcast is now available - but will be removed soon

8/27/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00+5.26%
8/19/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$36.00 ➝ $45.00+60.77%
8/9/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$34.00 ➝ $31.00+48.11%
5/10/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$44.00 ➝ $41.00+70.41%
1/9/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
11/16/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
10/16/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$46.00+64.29%
8/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$47.00+65.03%
2/23/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$40.00 ➝ $45.00+31.31%
1/30/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$57.00 ➝ $59.00+88.68%
1/6/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$44.00 ➝ $51.00+93.55%
11/18/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$52.00 ➝ $57.00+138.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:53 AM ET.


EVH Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Evolent Health is $29.50, with a high forecast of $45.00 and a low forecast of $16.00.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last twelve months. There is currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVH shares.

According to analysts, Evolent Health's stock has a predicted upside of 132.83% based on their 12-month stock forecasts.

Over the previous 90 days, Evolent Health's stock had 1 upgrade and 1 downgrade by analysts.

Evolent Health has been rated by research analysts at Barclays, Citigroup, JPMorgan Chase & Co., KeyCorp, Oppenheimer, Royal Bank of Canada, Stephens, and Truist Financial in the past 90 days.

Analysts like Evolent Health more than other "computer and technology" companies. The consensus rating for Evolent Health is Buy while the average consensus rating for "computer and technology" companies is Moderate Buy. Learn more on how EVH compares to other companies.


This page (NYSE:EVH) was last updated on 11/15/2024 by MarketBeat.com Staff
From Our Partners